183 related articles for article (PubMed ID: 33213205)
1. Cost-effectiveness of treatments for HER2-positive metastatic breast cancer and associated metastases: an overview of systematic reviews.
Diaby V; Almutairi RD; Babcock A; Moussa RK; Ali A
Expert Rev Pharmacoecon Outcomes Res; 2021 Jun; 21(3):353-364. PubMed ID: 33213205
[No Abstract] [Full Text] [Related]
2. A review of systematic reviews of the cost-effectiveness of hormone therapy, chemotherapy, and targeted therapy for breast cancer.
Diaby V; Tawk R; Sanogo V; Xiao H; Montero AJ
Breast Cancer Res Treat; 2015 May; 151(1):27-40. PubMed ID: 25893588
[TBL] [Abstract][Full Text] [Related]
3. Trastuzumab Emtansine for Treating HER2-Positive, Unresectable, Locally Advanced or Metastatic Breast Cancer After Treatment with Trastuzumab and a Taxane: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Squires H; Stevenson M; Simpson E; Harvey R; Stevens J
Pharmacoeconomics; 2016 Jul; 34(7):673-80. PubMed ID: 26892972
[TBL] [Abstract][Full Text] [Related]
4. Lapatinib activity in metastatic human epidermal growth factor receptor 2-positive breast cancers that received prior therapy with trastuzumab, pertuzumab, and/or ado-trastuzumab emtansine (T-DM1).
Baez-Vallecillo L; Raghavendra AS; Hess KR; Barcenas CH; Moulder SL; Tripathy D; Valero V; Murthy RK
Breast Cancer Res Treat; 2019 Jul; 176(1):227-234. PubMed ID: 30977027
[TBL] [Abstract][Full Text] [Related]
5. Lapatinib and trastuzumab in combination with an aromatase inhibitor for the first-line treatment of metastatic hormone receptor-positive breast cancer which over-expresses human epidermal growth factor 2 (HER2): a systematic review and economic analysis.
Fleeman N; Bagust A; Boland A; Dickson R; Dundar Y; Moonan M; Oyee J; Blundell M; Davis H; Armstrong A; Thorp N
Health Technol Assess; 2011; 15(42):1-93, iii-iv. PubMed ID: 22152751
[TBL] [Abstract][Full Text] [Related]
6. A phase II study of trastuzumab emtansine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who were previously treated with trastuzumab, lapatinib, an anthracycline, a taxane, and capecitabine.
Krop IE; LoRusso P; Miller KD; Modi S; Yardley D; Rodriguez G; Guardino E; Lu M; Zheng M; Girish S; Amler L; Winer EP; Rugo HS
J Clin Oncol; 2012 Sep; 30(26):3234-41. PubMed ID: 22649126
[TBL] [Abstract][Full Text] [Related]
7. Trastuzumab Emtansine (T-DM1) in Patients With HER2-Positive Metastatic Breast Cancer Previously Treated With Chemotherapy and 2 or More HER2-Targeted Agents: Results From the T-PAS Expanded Access Study.
Yardley DA; Krop IE; LoRusso PM; Mayer M; Barnett B; Yoo B; Perez EA
Cancer J; 2015; 21(5):357-64. PubMed ID: 26389758
[TBL] [Abstract][Full Text] [Related]
8. Ado-trastuzumab emtansine: a HER2-positive targeted antibody-drug conjugate.
Corrigan PA; Cicci TA; Auten JJ; Lowe DK
Ann Pharmacother; 2014 Nov; 48(11):1484-93. PubMed ID: 25082874
[TBL] [Abstract][Full Text] [Related]
9. Comparative effectiveness of trastuzumab emtansine versus lapatinib plus chemotherapy for HER2+ metastatic breast cancer.
Ramagopalan SV; Pisoni R; Zenin A; Rathore LS; Ray J; Sammon C
J Comp Eff Res; 2021 May; 10(7):595-602. PubMed ID: 33095031
[TBL] [Abstract][Full Text] [Related]
10. A global economic model to assess the cost-effectiveness of new treatments for advanced breast cancer in Canada.
Beauchemin C; Letarte N; Mathurin K; Yelle L; Lachaine J
J Med Econ; 2016 Jun; 19(6):619-29. PubMed ID: 26850287
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and Safety of HER2-Targeted Agents for Breast Cancer with HER2-Overexpression: A Network Meta-Analysis.
Yu Q; Zhu Z; Liu Y; Zhang J; Li K
PLoS One; 2015; 10(5):e0127404. PubMed ID: 25993646
[TBL] [Abstract][Full Text] [Related]
12. Trastuzumab emtansine (T-DM1) plus docetaxel with or without pertuzumab in patients with HER2-positive locally advanced or metastatic breast cancer: results from a phase Ib/IIa study.
Martin M; Fumoleau P; Dewar JA; Albanell J; Limentani SA; Campone M; Chang JC; Patre M; Strasak A; de Haas SL; Xu J; Garcia-Saenz JA
Ann Oncol; 2016 Jul; 27(7):1249-56. PubMed ID: 27052654
[TBL] [Abstract][Full Text] [Related]
13. Clinical benefit of treatment after trastuzumab emtansine for HER2-positive metastatic breast cancer: a real-world multi-centre cohort study in Japan (WJOG12519B).
Yokoe T; Kurozumi S; Nozawa K; Ozaki Y; Maeda T; Yazaki S; Onishi M; Fujimoto A; Nakayama S; Tsuboguchi Y; Iwasa T; Sakai H; Ogata M; Terada M; Nishimura M; Onoe T; Masuda J; Kurikawa M; Isaka H; Hagio K; Shimomura A; Okumura Y; Futamura M; Shimokawa M; Takano T
Breast Cancer; 2021 May; 28(3):581-591. PubMed ID: 33389616
[TBL] [Abstract][Full Text] [Related]
14. Evaluating the clinical effectiveness and safety of various HER2-targeted regimens after prior taxane/trastuzumab in patients with previously treated, unresectable, or metastatic HER2-positive breast cancer: a systematic review and network meta-analysis.
Paracha N; Reyes A; Diéras V; Krop I; Pivot X; Urruticoechea A
Breast Cancer Res Treat; 2020 Apr; 180(3):597-609. PubMed ID: 32100144
[TBL] [Abstract][Full Text] [Related]
15. Combination therapies for the treatment of HER2-positive breast cancer: current and future prospects.
Brandão M; Pondé NF; Poggio F; Kotecki N; Salis M; Lambertini M; de Azambuja E
Expert Rev Anticancer Ther; 2018 Jul; 18(7):629-649. PubMed ID: 29781317
[TBL] [Abstract][Full Text] [Related]
16. A randomized, controlled phase II trial of neoadjuvant ado-trastuzumab emtansine, lapatinib, and nab-paclitaxel versus trastuzumab, pertuzumab, and paclitaxel in HER2-positive breast cancer (TEAL study).
Patel TA; Ensor JE; Creamer SL; Boone T; Rodriguez AA; Niravath PA; Darcourt JG; Meisel JL; Li X; Zhao J; Kuhn JG; Rosato RR; Qian W; Belcheva A; Schwartz MR; Kaklamani VG; Chang JC
Breast Cancer Res; 2019 Sep; 21(1):100. PubMed ID: 31477168
[TBL] [Abstract][Full Text] [Related]
17. HER2-directed therapy for metastatic breast cancer.
Jelovac D; Emens LA
Oncology (Williston Park); 2013 Mar; 27(3):166-75. PubMed ID: 23687784
[TBL] [Abstract][Full Text] [Related]
18. Emerging approaches for treating HER2-positive metastatic breast cancer beyond trastuzumab.
Gradishar WJ
Ann Oncol; 2013 Oct; 24(10):2492-2500. PubMed ID: 23827380
[TBL] [Abstract][Full Text] [Related]
19. Cost-Effectiveness Analysis of Pertuzumab With Trastuzumab and Chemotherapy Compared to Trastuzumab and Chemotherapy in the Adjuvant Treatment of HER2-Positive Breast Cancer in the United States.
Garrison LP; Babigumira J; Tournier C; Goertz HP; Lubinga SJ; Perez EA
Value Health; 2019 Apr; 22(4):408-415. PubMed ID: 30975391
[TBL] [Abstract][Full Text] [Related]
20. A systematic review of dual targeting in HER2-positive breast cancer.
Kümler I; Tuxen MK; Nielsen DL
Cancer Treat Rev; 2014 Mar; 40(2):259-70. PubMed ID: 24080156
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]